D(+)-葡萄糖一水合物 | 77938-63-7

• 物质功能分类: 生物化工 - 糖类化合物 - 单糖
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: D(+)-葡萄糖一水合物
• 中文别名: 水合葡萄糖
• 英文名称: Dextrose Monohydrate
• 英文别名: (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal;hydrate
• CAS: 77938-63-7
• 化学式: C6H14O7
• 分子量: 198.17
• InChiKey: SPFMQWBKVUQXJV-BTVCFUMJSA-N

物化性质

• 溶解度：
  H2O：1 M，透明，无色

计算性质

• 辛醇/水分配系数(LogP)：
  -4.2
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  119
• 氢给体数：
  6
• 氢受体数：
  7

安全信息

• WGK Germany：
  3

SDS

Name:	D(+)-Glucose monohydrate Material Safety Data Sheet
Synonym:	Dextros
CAS:	77938-63-7

Section 1 - Chemical Product MSDS Name:D(+)-Glucose monohydrate Material Safety Data Sheet
Synonym:Dextros

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
77938-63-7	D(+)-Glucose monohydrate		unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
Dust may cause mechanical irritation. Low hazard for normal industrial handling.
Skin:
Dust may cause mechanical irritation. Low hazard for usual industrial handling.
Ingestion:
No hazard expected in normal industrial use.
Inhalation:
No hazard expected in normal industrial use. Inhalation of dust may cause respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. If irritation develops, get medical aid.
Skin:
Get medical aid if irritation develops or persists. Flush skin with plenty of soap and water.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. Get medical aid if cough or other symptoms appear.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. Dusts at sufficient concentrations can form explosive mixtures with air.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Avoid generating dusty conditions.

---

Section 7 - HANDLING and STORAGE
Handling:
Use with adequate ventilation. Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 77938-63-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystals
Color: off-white
Odor: odorless
pH: 4 @ 20% aq. sol.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 86 deg C
Autoignition Temperature: 380 deg C ( 716.00 deg F)
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: 146 deg C
Solubility in water: 47 g/100 ml
Specific Gravity/Density:
Molecular Formula: C6H12O6.H2O
Molecular Weight: 198.17

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong acids.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 77938-63-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
D(+)-Glucose monohydrate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Ecotoxicity:
log Pow = -3.29

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 77938-63-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 77938-63-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 77938-63-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  D(+)-葡萄糖一水合物 、 Ammonium citrate tribasic 反应 0.5h， 生成 Triammonium citrate dextrose
  参考文献：
  名称：

  Binder And Wood Board Product From Maillard Reactants

  摘要：

  粘合剂用于生产或促进非或松散组装的物质的凝聚。

  公开号：

  US20100130649A1
• 作为产物：
  描述：

  葡萄糖 以 水 为溶剂， 生成 D(+)-葡萄糖一水合物
  参考文献：
  名称：

  US20150261923A1

  摘要：

  公开号：
• 作为试剂：
  描述：

  苯甲醇 、 [(2S)-butan-2-yl] 2-[3-[4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl]-1-benzofuran-2-yl]acetate;2,3-dihydroxybutanedioic acid 、 2-(3-[4-[2-(二乙基氨基)乙氧基]-3,5-二碘苯甲酰基]-1-苯并呋喃-2-基)乙酸 (2S)-丁-2-基酯 以 水 、 D(+)-葡萄糖一水合物 为溶剂， 反应 0.01h， 生成 Benzyl Alcohol Budiodarone Tartrate
  参考文献：
  名称：

  BUDIODARONE FORMULATIONS

  摘要：

  本发明涉及包含苯甲醇和布地奥酮的溶液的布地奥酮制剂，其中当与水溶液接触时，布地奥酮的水溶性约为每毫升200毫克至1250毫克。布地奥酮制剂可以高度浓缩并具有稳定性，但制剂也可以稀释并且可以轻松快速地输送给受试者。

  公开号：

  US20140309296A1

文献信息

• [EN] 3-(3,5-DISUBSTITUTED-4-HYDROXYPHENYL)PROPIONAMIDE DERIVATIVES AS CATHEPSIN B INHIBITORS<br/>[FR] DERIVES DE 4-HYDROXYPHENYL-3-3,5-DISUBSTITUE-PROPIONAMIDE EN TANT QU'INHIBITEURS DE CATHEPSINE B
  申请人：AXYS PHARM INC

  公开号：WO2004026851A1

  公开（公告）日：2004-04-01

  The present invention is directed to novel 3-(3,5-disubstituted-4-hydroxyphenyl)-propionamide derivatives that are inhibitors of Cathepsin B. Pharmaceutical composition comprising these compounds, method of treating diseases mediated by Cathepsin B, utilizing these compounds and methods of preparing these compounds are also disclosed.

  本发明涉及一种新型的3-(3,5-二取代-4-羟基苯基)-丙酰胺衍生物，它们是Cathepsin B的抑制剂。还公开了包含这些化合物的药物组合物、治疗由Cathepsin B介导的疾病的方法、利用这些化合物的方法以及制备这些化合物的方法。
• [EN] PHENOTHIAZINE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE PHÉNOTHIAZINE ET LEURS UTILISATIONS
  申请人：CAMP4 THERAPEUTICS CORP

  公开号：WO2019195789A1

  公开（公告）日：2019-10-10

  The present invention provides phenothiazine compounds, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment of various diseases or conditions, for example ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA).

  本发明提供了吩噻嗪化合物，其制备方法，包含该化合物的药物组合物，以及在治疗各种疾病或症状中使用该化合物或组合物，例如核糖体紊乱和核糖体病，例如钻石-布莱克范贫血（DBA）。
• RENIN INHIBITORS
  申请人：Jones Benjamin

  公开号：US20100210635A1

  公开（公告）日：2010-08-19

  Compounds, pharmaceutical compositions, kits and methods are provided for use with Renin that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.

  提供了用于与Renin一起使用的化合物、药物组合物、试剂盒和方法，其中包括从以下组中选择的化合物：其中变量如本文所定义。
• SUBSTITUTED 2,4 DIAMINO-QUINOLINE AS NEW MEDICAMENT FOR FIBROSIS, AUTOPHAGY AND CATHEPSINS B (CTSB), L (CTSL) AND D (CTSD) RELATED DISEASES
  申请人：Genoscience Pharma SAS

  公开号：EP3620164A1

  公开（公告）日：2020-03-11

  The present invention relates to novel 2-primary amino-4-secondary amino-quinoline derivatives, their manufacture, pharmaceutical compositions comprising them and their use as medicaments. The active compounds of the present invention can be useful as a medicament in the treatment and/or the decreasing and/or the prevention of fibrosis and/or fibrosis related diseases, or for use as a medicament in the treatment and/or the decreasing and/or the prevention of the autophagy and/or autophagy related diseases and for the inhibition of the autophagy flux, or for use in the inhibition of cathepsins B (CTSB), L (CTSL) and/or D (CTSD) and/or cathepsins B (CTSB), L (CTSL) and/or D (CTSD) related diseases; with the proviso that said compounds are not to be used for the treatment of any forms of cancers.

  本发明涉及新型2-初级氨基-4-次级氨基喹啉衍生物，其制备方法，包含它们的药物组合物以及它们作为药物的用途。本发明的活性化合物可用作药物治疗和/或减少和/或预防纤维化和/或与纤维化相关疾病，或用作药物治疗和/或减少和/或预防自噬和/或与自噬相关疾病以及抑制自噬通量，或用于抑制蛋白酶B（CTSB）、L（CTSL）和/或D（CTSD）和/或与蛋白酶B（CTSB）、L（CTSL）和/或D（CTSD）相关疾病；但所述化合物不得用于治疗任何形式的癌症。
• ACETYL CoA CARBOXYLASE INHIBITORS
  申请人：Chang Edcon

  公开号：US20090253725A1

  公开（公告）日：2009-10-08

  The present invention relates to acetyl coenzyme-A carboxylase (“ACC”) inhibiting compounds of the formula wherein the variables are as defined herein. In particular, the present invention relates to ACC1 and/or ACC2 inhibitors, compositions of matter, kits and articles of manufacture comprising these compounds, methods for inhibiting ACC1 and/or ACC2, and methods of making the inhibitors.

  本发明涉及乙酰辅酶A羧化酶（“ACC”）抑制化合物，其化学式如下 其中变量如本文所述定义。特别是，本发明涉及ACC1和/或ACC2抑制剂，包含这些化合物的物质、套件和制品，抑制ACC1和/或ACC2的方法，以及制造抑制剂的方法。